Adilia Hormigo, MD, PhD
-
- Positions
- PROFESSOR | Neurology
- PROFESSOR | Neurosurgery
- PROFESSOR | Medicine
-
- Specialty
- Neurology
-
- Languages
- Portuguese
- French
- Spanish
- English
-
- Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai St. Luke's and Mount Sinai West
- The Mount Sinai Hospital
-
- Phone
- Tisch Cancer Institute 212-824-8579 212-824-8579
Book an Appointment - Adilia Hormigo, MD, PhD
Adilia Hormigo, MD, PhD is Director of the Neuro-Oncology Program for The Mount SinaiHospital and the Mount Sinai Health System, and Professor in the Department of Neurology, Medicine (Division of Hematology-Oncology), and Neurosurgery. She is a neuro-oncologist specializing in the care of patients with primary brain tumors, CNS metastases, and the neurological complications of cancer and its treatment. She employs a multidisciplinary team approach to ensure that patients receive compassionate, comprehensive care.
Dr. Hormigo obtained her MD with honors from the University of Lisbon Medical School in Portugal, and her PhD from New York University. She completed residencies in Neurology at the University Hospital of Lisbon Medical School, Portuguese Oncological Institute and New York Presbyterian-Weill Medical College of Cornell University and Memorial Sloan-Kettering Cancer Center. She completed both research and clinical neuro-oncology fellowships under Jerome B. Posner. She served as faculty at Memorial Sloan-Kettering Cancer Center and Cornell University. She trained a number of fellows, many of whom are faculty in leading programs of neuro-oncology in the country and abroad.
Her clinical and translational research focuses on new strategies including personalized treatment for patients with brain tumors with emphasis on immunotherapy, developing new biomarkers and studying the microenvironment of brain tumors. Her goal is to achieve the highest level of patient care and clinical excellence. She sees patients at the Ruttenberg Treatment Center of the Tisch Cancer Institute.
Certification
Neurology, American Board of Psychiatry and Neurology
Clinical Focus
- Brain Metastasis
- Brain Tumors
- Lumbar Puncture
- Paraneoplastic Syndromes, Central Nervous System
- Primary Central Nervous System Lymphoma
- Spinal Cord Tumors
Research Topics
Angiogenesis, Anti-Tumor Therapy, Brain, Cancer, Immunology, Metastasis, Stem Cells, Tumorigenesis
Education
MD, Faculdade de Medicina Lisboa
Research Fellow, Memorial Sloan-Kettering Cancer Center
PhD, New York University
Fellow, Memorial Sloan-Kettering Cancer Center
Internship, Neurology
Universidade De Lisboa
Residency, Neurology
Universidade De Lisboa
Internship, Internal Medicine
New York Presbyterian - Weill Cornell Medical Center
Residency, Neurology
New York Presbyterian - Weill Cornell Medical Center
Languages
Portuguese, French, Spanish, English
2013
Fellow
American Neurological Association
2012
Advanced Techniques in Molecular Neuroscience
Cold Spring Harbor Laboratory
2005
Excellence in Teaching Award for the Neurology Clerkship
Weill Medical College of Cornell University
2003
Resident Award
American Academy of Neurology
1990
Second UCB Neurology Award
Portuguese Society of Neurology
1989
Biofarma
Portuguese Society of Neurology
Developing Personalized Medicine to Treat Patients with Brain Tumors
Dr. Hormigo's research focuses on developing personalized medicine to treat patients with brain tumors. She uses a multidisciplinary approach that includes neuropathology, bioinformatics, biochemistry and the Cancer Vaccine and Cell Therapy laboratory at the Tisch Cancer Institute to develop a new immunotherapy-based treatment. Mutations in glioblastoma lead to the formation of neoantigens. These neoantigens are not present in normal cells. Her treatment targets those neoantigens of tumors and it is given to the patient in a form of vaccine to activate the immune system and eliminate the cancer cells. Her team is also developing new methods to increase drug penetration to the brain and to determine other approaches that will enhance the effect of immunotherapy.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Hormigo did not report having any of the following types of financial relationships with industry during 2019 and/or 2020: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website.
Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.